In the validation cohort , levels of HbA1c were decreased by 2.6 mmoles/mole ( 0.23 % ) ( P < 0.001 ) after treatment , and MTXGlu3 was associated with decreased levels of HbA1c ( = -0.26 , P = 0.018 ) .